GSK announces further initiatives to advance openness and collaboration to help tackle global health challenges
11 October 2012 | By GlaxoSmithKline
Greater openness, transparency and collaboration...
List view / Grid view
11 October 2012 | By GlaxoSmithKline
Greater openness, transparency and collaboration...
9 October 2012 | By GlaxoSmithKline
GSK welcomes the announcement from GAVI Alliance...
4 October 2012 | By GlaxoSmithKline
Dolutegravir is not yet approved as a treatment for HIV...
1 October 2012 | By GlaxoSmithKline
The pivotal Phase III study COMPARZ has met its primary endpoint...
26 September 2012 | By GlaxoSmithKline
GSK announces the following changes to its Board and Committee structure...
26 September 2012 | By GlaxoSmithKline
Japanese New Drug Application (JNDA) submitted for COPD and asthma....
17 September 2012 | By GlaxoSmithKline
GSK has submitted a regulatory application in the European Union seeking approval of an additional indication for Synflorix™...
13 September 2012 | By GlaxoSmithKline
GlaxoSmithKline has acquired five million newly issued shares of Response Genetics Inc...
24 August 2012 | By GlaxoSmithKline
GSK confirms its intention to commence global filings from the end of 2012...
23 August 2012 | By GlaxoSmithKline
“The start of the Phase III programme in rheumatoid arthritis is an important milestone in our collaboration with Janssen Biologics.”
15 August 2012 | By GlaxoSmithKline
GSK has reached agreement to divest the majority of its “Classic Brands” in Australia...
7 August 2012 | By GlaxoSmithKline
The European Commission has granted pazopanib marketing authorisation...
3 August 2012 | By GlaxoSmithKline
GlaxoSmithKline has completed its acquisition of Human Genome Sciences for US$3.6 billion...
3 August 2012 | By GlaxoSmithKline
GlaxoSmithKline announced regulatory submissions in the European Union and US...
30 July 2012 | By GlaxoSmithKline
GSK announced the results of its initial tender offer for all outstanding shares of HGS...